| Entry |
|
|---|
| Name |
Procainamide hydrochloride (JP16/USP);
Procan SR (TN);
Procanbid (TN);
Pronestyl (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C13H21N3O. HCl
|
|---|
| Exact mass |
271.1451
|
|---|
| Mol weight |
271.7863
|
|---|
| Structure |
     |
|---|
| Activity |
Cardiac depressant [anti-arrhythmic]
|
|---|
| Remark |
Therapeutic category: ATC code: |
|---|
| Comment |
Class I antiarrhythmic agent (Ia)
|
|---|
| Target |
voltage-gated sodium channel (SCN1A) blocker [HSA: 6323] [KO: K04833]; voltage-gated sodium channel (SCN2A) blocker [HSA: 6326] [KO: K04834]; voltage-gated sodium channel (SCN3A) blocker [HSA: 6328] [KO: K04836]; voltage-gated sodium channel (SCN4A) blocker [HSA: 6329] [KO: K04837]; voltage-gated sodium channel (SCN5A) blocker [HSA: 6331] [KO: K04838]; voltage-gated sodium channel (SCN8A) blocker [HSA: 6334] [KO: K04840]; voltage-gated sodium channel (SCN9A) blocker [HSA: 6335] [KO: K04841] |
|---|
| Metabolism |
Transporter: SLC22A2 [HSA: 6582], SLC22A3 [HSA: 6581]
|
|---|
| Interaction |
Transporter inhibition: SLC47A1 [HSA: 55244]
 |
|---|
| Structure map |
| Antipsychotics | | Antiarrhythmic drugs | | Dopamine receptor agonists/antagonists | | Sodium channel blocking drugs |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
212 Antiarrhythmic agents
2121 Procainamides
D00477 Procainamide hydrochloride (JP16/USP)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01B ANTIARRHYTHMICS, CLASS I AND III
C01BA Antiarrhythmics, class Ia
C01BA02 Procainamide
D00477 Procainamide hydrochloride (JP16/USP)
USP drug classification [BR:br08302]
Cardiovascular Agents
Antiarrhythmics
Procainamide
D00477 Procainamide hydrochloride (JP16/USP)
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated cation channels
Na+ channel, SCN alpha, NaV1.x
voltage-gated sodium channel (SCN1A) [HSA:6323] [KO:K04833]
Procainamide [ATC:C01BA02]
D00477 Procainamide hydrochloride (JP16/USP)
voltage-gated sodium channel (SCN2A) [HSA:6326] [KO:K04834]
Procainamide [ATC:C01BA02]
D00477 Procainamide hydrochloride (JP16/USP)
voltage-gated sodium channel (SCN3A) [HSA:6328] [KO:K04836]
Procainamide [ATC:C01BA02]
D00477 Procainamide hydrochloride (JP16/USP)
voltage-gated sodium channel (SCN4A) [HSA:6329] [KO:K04837]
Procainamide [ATC:C01BA02]
D00477 Procainamide hydrochloride (JP16/USP)
voltage-gated sodium channel (SCN5A) [HSA:6331] [KO:K04838]
Procainamide [ATC:C01BA02]
D00477 Procainamide hydrochloride (JP16/USP)
voltage-gated sodium channel (SCN8A) [HSA:6334] [KO:K04840]
Procainamide [ATC:C01BA02]
D00477 Procainamide hydrochloride (JP16/USP)
voltage-gated sodium channel (SCN9A) [HSA:6335] [KO:K04841]
Procainamide [ATC:C01BA02]
D00477 Procainamide hydrochloride (JP16/USP)
 |
|---|
| Other DBs |
CAS: 614-39-1 PubChem: DrugBank: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 18
1 C8y C 18.9171 -15.8141
2 C5a C 20.1248 -16.5201
3 C8x C 18.9231 -14.4081
4 C8x C 17.6921 -16.5084
5 N1b N 21.3384 -15.8257
6 O5a O 20.1190 -17.9203
7 C8x C 17.7154 -13.6964
8 C8x C 16.4902 -15.7966
9 C1b C 22.5518 -16.5258
10 C8y C 16.5018 -14.4022
11 C1b C 23.7594 -15.8317
12 N1a N 15.2884 -13.6906
13 N1c N 24.9728 -16.5318
14 C1b C 26.1805 -15.8433
15 C1b C 24.9671 -17.9320
16 C1a C 27.3941 -16.5375
17 C1a C 26.1747 -18.6437
18 X Cl 30.9992 -17.3018
BOND 17
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 1
5 2 6 2
6 3 7 1
7 4 8 2
8 5 9 1
9 7 10 2
10 9 11 1
11 10 12 1
12 11 13 1
13 13 14 1
14 13 15 1
15 14 16 1
16 15 17 1
17 8 10 1
|
|---|
